Quantitative aspects of vibration-induced mortality.
D000661:Amphetamine / Q000627:therapeutic use; D000818:Animals; D001285:Atropine / Q000627:therapeutic use; D002707:Chlordiazepoxide / Q000627:therapeutic use; D003913:Dextroamphetamine / Q000627:therapeutic use; D004837:Epinephrine / Q000627:therapeutic use; D006584:Hexamethonium Compounds / Q000627:therapeutic use; D007545:Isoproterenol / Q000627:therapeutic use; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009041:Motion Sickness / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D009388:Neostigmine / Q000627:therapeutic use; D010634:Phenobarbital / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010656:Phenylephrine / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D013223:Statistics as Topic; D013566:Sympathomimetics / Q000627:therapeutic use; D013997:Time Factors; D014732:Vibration / Q000009:adverse effects*
D006584:Hexamethonium Compounds; D010879:Piperazines; D013566:Sympathomimetics; D010643:Phenoxybenzamine; D010656:Phenylephrine; D009388:Neostigmine; D002707:Chlordiazepoxide; D001285:Atropine; D008012:Lidocaine; D000661:Amphetamine; D007545:Isoproterenol; D003913:Dextroamphetamine; D004837:Epinephrine; D010634:Phenobarbital